Redalpine

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Carvolution is a Swiss mobility company offering a fully digital car subscription service. Through an online platform, customers choose a vehicle and pay a fixed monthly price that covers most costs, including vehicle registration, taxes, insurance, maintenance, and tires; fuel or charging costs are not included. The service removes long-term commitments and the traditional purchase or lease, providing an alternative to ownership. Based in Bern, Carvolution provides a streamlined experience by integrating delivery and ongoing vehicle management into a single subscription, with all administrative and service needs handled as part of the monthly fee. The model positions Carvolution as a modern, convenient mobility solution that simplifies access to a car while delivering predictable, all-inclusive costs.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Daedalean AG, founded in 2016 and headquartered in Zurich, Switzerland, specializes in developing autonomous flight control systems for electric personal aircraft. The company focuses on creating machine-learning-based avionics systems aimed at enhancing the safety and efficiency of civil aviation. With a team of over 150 professionals, including experts in machine learning, aviation software engineering, flight testing, and safety certification, Daedalean is actively working on its flagship AI-based certified products, Pilot Eye™ and Ailumina Vista™, designed for visual traffic detection in fixed-wing aircraft and helicopters. Additionally, the company is innovating in areas such as non-GNSS positioning, landing guidance, and power line detection. Daedalean has formed partnerships with aviation regulators and has collaborated with agencies like EASA and the FAA to facilitate the certification process for its machine-learning systems, aiming to set new standards in safety-critical aviation applications.

Carvolution is a Swiss mobility company offering a fully digital car subscription service. Through an online platform, customers choose a vehicle and pay a fixed monthly price that covers most costs, including vehicle registration, taxes, insurance, maintenance, and tires; fuel or charging costs are not included. The service removes long-term commitments and the traditional purchase or lease, providing an alternative to ownership. Based in Bern, Carvolution provides a streamlined experience by integrating delivery and ongoing vehicle management into a single subscription, with all administrative and service needs handled as part of the monthly fee. The model positions Carvolution as a modern, convenient mobility solution that simplifies access to a car while delivering predictable, all-inclusive costs.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Carvolution is a Swiss mobility company offering a fully digital car subscription service. Through an online platform, customers choose a vehicle and pay a fixed monthly price that covers most costs, including vehicle registration, taxes, insurance, maintenance, and tires; fuel or charging costs are not included. The service removes long-term commitments and the traditional purchase or lease, providing an alternative to ownership. Based in Bern, Carvolution provides a streamlined experience by integrating delivery and ongoing vehicle management into a single subscription, with all administrative and service needs handled as part of the monthly fee. The model positions Carvolution as a modern, convenient mobility solution that simplifies access to a car while delivering predictable, all-inclusive costs.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Daedalean AG, founded in 2016 and headquartered in Zurich, Switzerland, specializes in developing autonomous flight control systems for electric personal aircraft. The company focuses on creating machine-learning-based avionics systems aimed at enhancing the safety and efficiency of civil aviation. With a team of over 150 professionals, including experts in machine learning, aviation software engineering, flight testing, and safety certification, Daedalean is actively working on its flagship AI-based certified products, Pilot Eye™ and Ailumina Vista™, designed for visual traffic detection in fixed-wing aircraft and helicopters. Additionally, the company is innovating in areas such as non-GNSS positioning, landing guidance, and power line detection. Daedalean has formed partnerships with aviation regulators and has collaborated with agencies like EASA and the FAA to facilitate the certification process for its machine-learning systems, aiming to set new standards in safety-critical aviation applications.

RosieReality is a company based in Zurich, Switzerland, founded in 2017, that specializes in developing an educational mobile application named Rosie. Aimed at children aged 9 and up, the app utilizes augmented reality to create an engaging learning experience focused on science and basic robotics coding. Through the interactive platform, users can program Rosie the Robot using magical 3D shapes to solve AR puzzles and complete various challenges. This gamified approach not only fosters curiosity in scientific exploration but also offers parents a fun and educational tool to support their children's learning in technology and coding.

Carvolution is a Swiss mobility company offering a fully digital car subscription service. Through an online platform, customers choose a vehicle and pay a fixed monthly price that covers most costs, including vehicle registration, taxes, insurance, maintenance, and tires; fuel or charging costs are not included. The service removes long-term commitments and the traditional purchase or lease, providing an alternative to ownership. Based in Bern, Carvolution provides a streamlined experience by integrating delivery and ongoing vehicle management into a single subscription, with all administrative and service needs handled as part of the monthly fee. The model positions Carvolution as a modern, convenient mobility solution that simplifies access to a car while delivering predictable, all-inclusive costs.

Founded in 2017, TOLREMO therapeutics is a biotechnology company based in Muttenz, Switzerland. It specializes in developing small molecule therapies to target and eradicate cancer cells that cause drug resistance, aiming to prolong the lives of cancer patients.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Bexio AG is a Swiss company that specializes in providing cloud-based business and accounting software tailored for small and medium-sized enterprises. Founded in 2013 and based in Rapperswil, the company was previously known as easySYS AG before rebranding in 2015. Bexio AG focuses on simplifying accounting processes and enhancing business management through its user-friendly platform, which employs a standardized interface to facilitate interactions between businesses and their trustees, banks, and service providers. As of mid-2018, Bexio operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG, reflecting its commitment to supporting the growth and efficiency of small businesses in Switzerland.

Founded in 2013 by Dennis Just and Christina Kehl, Knip is a technology company specializing in insurance management. Headquartered in Zurich with offices in Berlin and Belgrade, the company employs over 100 individuals. Knip's flagship product is an innovative mobile application that enables users to track their insurance policies, premiums, and benefits. The platform offers electronic adjustment of premiums, execution of new policies, cancellation of old ones, and unbiased advice from insurance experts.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

TrekkSoft is a software solution tailored for tour and activity providers, enabling them to efficiently manage and market their businesses. Founded in 2010, the company offers a web-based platform that includes a booking system, payment processing, and a channel manager. This comprehensive solution automates administrative tasks, allowing users to focus on increasing bookings and streamlining operations. TrekkSoft’s platform facilitates online and offline sales, helping businesses connect with a global customer base while ensuring prompt payouts to their bank accounts. The company operates on a commission model, charging rates based on the chosen service package, which range from 2% to 3% for online transactions. With offices in Interlaken, Switzerland, and New York, United States, TrekkSoft employs a diverse team of adventure enthusiasts, user experience specialists, marketers, and programmers dedicated to supporting the needs of tour operators, activity providers, travel agents, and event organizers.

Bexio AG is a Swiss company that specializes in providing cloud-based business and accounting software tailored for small and medium-sized enterprises. Founded in 2013 and based in Rapperswil, the company was previously known as easySYS AG before rebranding in 2015. Bexio AG focuses on simplifying accounting processes and enhancing business management through its user-friendly platform, which employs a standardized interface to facilitate interactions between businesses and their trustees, banks, and service providers. As of mid-2018, Bexio operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG, reflecting its commitment to supporting the growth and efficiency of small businesses in Switzerland.

Founded in 2006 as an ETH Zurich spin-off, Redbiotec is a biotech company based in Zurich-Schlieren. Initially known for its vaccine innovations, it sold its CMV vaccine business to Pfizer and developed an HSV-2 immunotherapy. Currently, the company focuses on developing bacteria-based gene therapies to treat cancer and genetic disorders using its proprietary platform designed to overcome delivery challenges.

Founded in 2013 by Dennis Just and Christina Kehl, Knip is a technology company specializing in insurance management. Headquartered in Zurich with offices in Berlin and Belgrade, the company employs over 100 individuals. Knip's flagship product is an innovative mobile application that enables users to track their insurance policies, premiums, and benefits. The platform offers electronic adjustment of premiums, execution of new policies, cancellation of old ones, and unbiased advice from insurance experts.

TrekkSoft is a software solution tailored for tour and activity providers, enabling them to efficiently manage and market their businesses. Founded in 2010, the company offers a web-based platform that includes a booking system, payment processing, and a channel manager. This comprehensive solution automates administrative tasks, allowing users to focus on increasing bookings and streamlining operations. TrekkSoft’s platform facilitates online and offline sales, helping businesses connect with a global customer base while ensuring prompt payouts to their bank accounts. The company operates on a commission model, charging rates based on the chosen service package, which range from 2% to 3% for online transactions. With offices in Interlaken, Switzerland, and New York, United States, TrekkSoft employs a diverse team of adventure enthusiasts, user experience specialists, marketers, and programmers dedicated to supporting the needs of tour operators, activity providers, travel agents, and event organizers.

Onsite Lab Holding AG, based in Zug, Switzerland, focuses on the development and manufacture of rapid flow-through diagnostics and technologies primarily for HIV and hepatitis viruses. Through its subsidiary MedMira, the company offers advanced rapid tests that deliver results within three minutes, facilitating quick and efficient diagnosis. These products are designed for use in point-of-care settings, laboratories, and hospitals, both in the United States and internationally. MedMira's patented technology allows for multiple results in a single test, enhancing its utility in mass testing scenarios. The company emphasizes high-quality standards while ensuring economical sustainability, with its facilities holding various certifications, including ISO and approvals from FDA and CE.

TrekkSoft is a software solution tailored for tour and activity providers, enabling them to efficiently manage and market their businesses. Founded in 2010, the company offers a web-based platform that includes a booking system, payment processing, and a channel manager. This comprehensive solution automates administrative tasks, allowing users to focus on increasing bookings and streamlining operations. TrekkSoft’s platform facilitates online and offline sales, helping businesses connect with a global customer base while ensuring prompt payouts to their bank accounts. The company operates on a commission model, charging rates based on the chosen service package, which range from 2% to 3% for online transactions. With offices in Interlaken, Switzerland, and New York, United States, TrekkSoft employs a diverse team of adventure enthusiasts, user experience specialists, marketers, and programmers dedicated to supporting the needs of tour operators, activity providers, travel agents, and event organizers.

InSphero specializes in the production and application of organotypic 3D cell culture models for various applications. It offers a range of assay-ready microtissues derived from liver, pancreas, tumor, heart, brain, and skin cells, along with optimized media and platforms for their generation and cultivation. The company's products include human and rat liver microtissues, pancreatic microislets, tumor microtissues, custom-made microtissues, cytotoxicity assay kits, and a human liver disease discovery platform. InSphero also provides services such as hepatotoxicity testing, oncology service packs, and embryonic stem cell test services. Its 3D InSight microtissues are used in toxicity testing, drug metabolism studies, cancer research, stem cell research, and disease modeling.

Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax is a preclinical stage company. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of CMV and a further undisclosed field.